Aflibercept 8 mg in Patients with RVO

In this segment, Dr. Harit Bhatt and Dr. Deepak Sambhara discuss the pivotal QUASAR trial, which evaluated aflibercept 8 mg in patients with retinal vein occlusion (RVO). Dr. Sambhara outlines the study design, highlighting that both 3- and 5-dose loading regimens (Q8 intervals) achieved comparable efficacy and anatomical improvement to aflibercept 2 mg, while requiring fewer injections. He emphasizes the significance of the trial’s treat-and-extend design, which, for the first time in RVO studies, allows both the standard 2 mg arm and the high-dose 8 mg arms to undergo interval extension—potentially demonstrating real-world durability advantages. Dr. Bhatt, whose site also participated in the trial, confirms similar findings, praising the robust visual gains, safety profile, and reduced treatment burden. Both experts express enthusiasm for the upcoming label approval and anticipate integrating aflibercept 8 mg into clinical practice to optimize outcomes and extend treatment intervals for RVO patients.